Effect of Aldosterone on Energy Starvation in Heart Failure

• Status: Completed
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

We plan to study the concept of "energy starvation" in heart failure by evaluation of patients with nonischemic dilated cardiomyopathy (NIDCM) (heart failure with reduced heart pump function due to causes other than heart attack). We will use a combination of positron emission tomography and magnetic resonance imaging to study metabolism, anatomy, function, blood flow and efficiency, before and after 6 months' treatment with the drug spironolactone which blocks the deleterious effects of the hormone aldosterone on the myocardium (heart muscle).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vanderbilt University; Vanderbilt University Medical Center
• Treatments: Spironolactone

Criteria

Inclusion Criteria:

• 18 years or older

• Nonischemic dilated cardiomyopathy

• Left ventricular ejection fraction 35% or less

• Stable heart failure symptoms

• Able to undergo both positron emission tomography and magnetic resonance imaging with gadolinium

• Able to tolerate treatment with spironolactone

Exclusion Criteria:

• Serum potassium >5.0

• Serum creatinine >2.5

• Contraindications to magnetic resonance imaging such as internal cardioverter-defibrillator.